ST Pharm is pleased to announce its participation in the ESMO Congress 2024, where we will present a poster session on Basroparib (STP1002), an innovative tankyrase inhibitor (TNKSi). This presentation will highlight the findings from a phase 1 clinical trial, marking a key development in cancer treatment.

Presentation Details:

• Title: First-In-Human Dose-Escalation Study of Basroparib (STP1002) in Patients with Advanced-Stage Solid Tumors
• Presentation Number: 633P
• Poster Display Date: Saturday, September 14, 2024
• On-Site Presentation Time: 12:00 PM - 1:00 PM

We invite attendees to visit our poster session to explore the promising results and advancements associated with Basroparib (STP1002).

For further information and to view the presentation schedule,
please visit: ESMO 2024 PresentationSchedule

For inquiries or additional information,
please contact us at stp.nddi@stpharm.co.kr.

We look forward to engaging with you at this prestigious event and sharing our latest research developments.